1221 / 1416
CNS:
RTOG-1205: Recurrent GBM. Randomized phase III trial of concurrent bevacizumab and
re
-
irradiation versus bevacizumab alone. Open. Permitting protons. Accrual 180 patients.
Prescription: 35 Gy in 10 fractions.
Randomization is between bevacizumab plus radiation versus bevacizumab alone, at the time of
next recurrence re-irradiation will be permitted.
NRG-BN001:
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or
Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant
Temozolomide in Patients With Newly Diagnosed Glioblastoma.
Standard fractionation 60 Gy in 30 fractions versus dose-escalated, hypofractionation 75 Gy in
30 fractions.
Hypothesis: prolonged overall survival from 16 months (standard Dose of 60 Gy) to 22 months
Randomization between dose, not modality. However, modalities will be compared
Accrual: 576 patients. Activated 10/2014
NRG: (Radiation Therapy Oncology Group – recently
integrated into new organization “NRG” (= NASBP,
RTOG, GOG):
Note:
Innova*ve concept to deal with difficul*es
of true randomiza*on between protons and
photons given referral reali*es and clinical
urgency to start RT